Abiomed, Inc. (ABMD)

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "IoMT Wearable Devices Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The IoMT wearable devices market was valued at USD 34.93 billion in 2023. It is expected to grow at a CAGR of 23.0% during the forecast period of 2024-2032 and attain a market value of USD 225.1 billion in 2032. The patent landscape is driven by advancements in sensor technology, AI integration, and connectivity solutions, enhancing diagnostic accuracy and personalised treatment. The global IoMT wearable devices patent landscape report offers an in-depth analysis of the dynamic patent environment. It explores innovations in sensor technologies, AI integration, and advanced connectivity solutions that are shaping the future of IoMT wearables. The report provides detailed segmentation by product type, modality, and application, highlighting key patents and emerging trends.

The U.S. health regulator on Thursday classified the recall of blood pumps by Abiomed, a Johnson & Johnson company, as the most serious and said their use could cause serious injuries or death.

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

DANVERS, Mass.--( BUSINESS WIRE )--Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI).

There's a lot more ahead for these market giants.

NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (“Offeror”), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the “Offer”) to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ: ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Elevate Credit, Inc. (NYSE: ELVT)'s  sale to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are an Elevate Credit shareholder, click here to learn more about your rights and options.

DANVERS, Mass.--( BUSINESS WIRE )--Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed's newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas.

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

The company is planting seeds for future growth.

The $16.6 billion acquisition shakes up MedTech.

Johnson & Johnson has outperformed the Dow so far this year.

Wilmington, Delaware--(Newsfile Corp. - November 4, 2022) - Rigrodsky Law, P.A. is investigating ABIOMED, Inc. ("ABIOMED") (NASDAQ: ABMD) regarding possible breaches of fiduciary duties and other violations of law related to ABIOMED's agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, ABIOMED's shareholders will receive $380.00 in cash plus one contingent value right per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-abiomed-inc.To contact Seth D.

NEW YORK , Nov. 2, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atlas Corp. (NYSE: ATCO)'s  sale to Poseidon Acquisition Corp. for $15.50 per share in cash. If you are an Atlas shareholder, click here to learn more about your rights and options.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

NEW YORK , Nov. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Abiomed, Inc. ("Abiomed" or the "Company") (NASDAQ: ABMD), in connection with its proposed tender offer by Johnson & Johnson (NYSE: JNJ). Under the tender offer, the Company's shareholders will receive $380.00 in cash, reflecting an enterprise value of approximately $16.6 billion, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35.00 for each share of Abiomed common stock owned.